About sotorasib
KRAS G12C inhibitor
Used for
- Treats certain advanced non-small-cell lung cancers with a KRAS G12C mutation after prior treatment.
Usual adult dose
960 mg by mouth once daily, with or without food, until the cancer worsens or side effects become unacceptable.
Common side effects
- Diarrhea, nausea, vomiting, or constipation
- Muscle or joint pain
- Fatigue
- Liver enzyme changes
Important warnings
- Can cause serious liver injury; liver tests are monitored during treatment.
- Can cause interstitial lung disease or pneumonitis; breathing symptoms require prompt assessment.
- Acid-reducing medicines can reduce absorption.
- May harm an unborn baby; effective contraception is recommended during treatment and for one week afterward.
Pregnancy
May cause fetal harm. Avoid use during pregnancy; effective contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Proton pump inhibitors and H2 blockers can lower sotorasib levels.
- Antacids can lower absorption; separate dosing by four hours.
- Can reduce levels of some medicines, including warfarin and hormonal contraceptives.
- Strong CYP3A inducers can reduce sotorasib levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.